参芪扶正注射液联合奥司他韦治疗病毒性肺炎患者的效果  

Effects of Shenqi Fuzheng injection combined with Oseltamivir in treatment of patients with viral pneumonia

作　　者：袁梦 靳志峰[1] 高伟超[1] YUAN Meng;JIN Zhifeng;GAO Weichao(Department of Emergency Medicine of Nanyang First People’s Hospital,Nanyang 473000 Henan,China)

机构地区：[1]南阳市第一人民医院急诊医学科,河南南阳473000

出　　处：《中国民康医学》2025年第5期99-103,共5页Medical Journal of Chinese People’s Health

摘　　要：目的:观察参芪扶正注射液联合奥司他韦治疗病毒性肺炎患者的效果。方法:选取2021年11月至2023年11月该院收治的80例病毒性肺炎患者进行前瞻性研究,按照随机数字表法将其分为对照组与研究组各40例。对照组采用奥司他韦治疗,研究组在对照组基础上联合参芪扶正注射液治疗。比较两组临床疗效、临床症状(咳嗽、发热、肺啰音)消失时间,治疗前后中医证候积分(发热咳嗽、痰黄痰鸣、胸闷气短)、肺功能指标[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)]水平、炎性因子[C反应蛋白(CRP)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+))水平,以及不良反应发生率。结果:研究组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);研究组咳嗽、发热、肺啰音消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组胸闷气短、痰黄痰鸣、发热咳嗽等中医证候积分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组FEV_(1)、FVC水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、TNF-α、IL-10水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均高于治疗前,且研究组高于对照组,两组CD8^(+)水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:参芪扶正注射液联合奥司他韦治疗病毒性肺炎患者可提高治疗总有效率和肺功能指标水平,缩短临床症状消失时间,改善T细胞亚群指标水平,以及降低中医证候积分和炎性因子水平,效果优于单纯奥司他韦治疗。Objective:To observe effects of Shenqi Fuzheng injection combined with Oseltamivir in treatment of patients with viral pneumonia.Methods:A prospective study was conducted on 80 patients with viral pneumonia admitted to this hospital from November 2021 to November 2023.They were divided into control group and study group according to the random number table method,40 cases each.The control group was treated with Oseltamivir,while the study group was treated with Shenqi Fuzheng injection on the basis of that of the control group.The clinical efficacy,the disappearance time of clinical symptoms (cough,fever,pulmonary rales),the TCM syndrome score (fever,cough,yellow and wheezy phlegm,chest tightness and shortness of breath),the lung function indexes[forced expiratory volume in one second (FEV_(1)),forced vital capacity (FVC)]levels,the inflammatory factors[C-reactive protein (CRP),interleukin-10 (IL-10),tumor necrosis factor-α (TNF-α)]levels,the T cell subsets (CD3^(+),CD4^(+),CD8^(+)) levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 92.50%(37/40),which was higher than 75.00%(30/40) in the control group,and the difference was statistically significant (P<0.05).The disappearance time of cough,fever and lung rale in the study group was shorter than that in the control group,and the difference was statistically significant (P<0.05).After the treatment,the scores of TCM syndromes such as chest tightness and shortness of breath,yellow and wheezy phlegm,fever and cough in the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant (P<0.05).After the treatment,the levels of FEV_(1) and FVC in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the difference was statistically significant (P<0.05).After the treatment,the levels of

关 键 词：参芪扶正注射液 奥司他韦 病毒性肺炎 肺功能 炎性因子 T细胞亚群 

分 类 号：R563.1[医药卫生—呼吸系统]